620.59
Medpace Holdings Inc stock is traded at $620.59, with a volume of 303.08K.
It is up +0.56% in the last 24 hours and up +0.09% over the past month.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
See More
Previous Close:
$617.15
Open:
$612.3
24h Volume:
303.08K
Relative Volume:
1.05
Market Cap:
$17.32B
Revenue:
$2.68B
Net Income/Loss:
$460.40M
P/E Ratio:
39.04
EPS:
15.8963
Net Cash Flow:
$711.00M
1W Performance:
+0.88%
1M Performance:
+0.09%
6M Performance:
+34.69%
1Y Performance:
+24.79%
Medpace Holdings Inc Stock (MEDP) Company Profile
Name
Medpace Holdings Inc
Sector
Industry
Phone
(513) 579-9911
Address
5375 MEDPACE WAY, CINCINNATI, OH
Compare MEDP vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MEDP
Medpace Holdings Inc
|
620.59 | 17.32B | 2.68B | 460.40M | 711.00M | 15.90 |
|
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-18-26 | Upgrade | TD Cowen | Sell → Hold |
| Feb-13-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-10-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-02-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Sep-03-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-29-25 | Downgrade | UBS | Neutral → Sell |
| Jul-23-25 | Downgrade | TD Cowen | Hold → Sell |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Apr-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-24-25 | Initiated | Leerink Partners | Market Perform |
| Oct-23-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-27-24 | Downgrade | UBS | Buy → Neutral |
| Sep-25-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-24 | Initiated | Truist | Hold |
| May-29-24 | Initiated | TD Cowen | Buy |
| May-28-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-24 | Initiated | Deutsche Bank | Hold |
| Feb-15-24 | Upgrade | UBS | Neutral → Buy |
| Oct-24-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-08-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-27-22 | Upgrade | UBS | Sell → Neutral |
| Sep-07-22 | Initiated | UBS | Sell |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Oct-02-20 | Upgrade | Truist | Hold → Buy |
| Jun-08-20 | Upgrade | Robert W. Baird | Underperform → Neutral |
| May-13-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Apr-30-20 | Upgrade | SunTrust | Sell → Hold |
| Apr-20-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Mar-17-20 | Downgrade | SunTrust | Hold → Sell |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Oct-31-18 | Upgrade | SunTrust | Hold → Buy |
| Sep-17-18 | Initiated | SunTrust | Hold |
| Jul-31-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-01-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-29-17 | Initiated | Raymond James | Mkt Perform |
| Jul-10-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
View All
Medpace Holdings Inc Stock (MEDP) Latest News
Insider Transaction: August J Troendle Sells $44.43M Worth Of Medpace Holdings Shares - Benzinga
Medpace Holdings, Inc. (MEDP) Stock Forecasts - Yahoo! Finance Canada
Have Insiders Sold Medpace Holdings Shares Recently? - simplywall.st
Medpace stock falls 2.07 percent as CEO sale surfaces - AD HOC NEWS
Medpace (MEDP) CEO sold 49,018 shares on Sept. 22 at a $628.11 average price. - Stock Titan
MEDP FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class ActionMEDP - TMX Newsfile
Medpace Holdings, Inc. (MEDP) Stock forecasts - Yahoo Finance UK
Mizuho maintains Outperform on Medpace, raises target to $586 - scanx.trade
Medpace Holdings Q3FY26 Results: Earnings call set for Oct 22 - scanx.trade
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 - Business Wire
Medpace Holdings President & CEO Trades $6.75M In Company Stock - Benzinga
Medpace Holdings (MEDP) Nears Earnings, Is The Stock Fully Valued? - finance.yahoo.com
Medpace Holdings Insider Sold Shares Worth $6,749,952, According to a Recent SEC Filing - Moomoo
Medpace (MEDP) Outperforms Broader Market: What You Need to Know - finance.yahoo.com
Medpace (NASDAQ:MEDP) CEO Sells $6,749,952.00 in Stock - MarketBeat
Medpace (NASDAQ: MEDP) CEO sells shares, holds 504,273 directly - Stock Titan
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Medpace Holdings, Inc.Common Stock (Nasdaq:MEDP) Price Chart - The Chronicle-Journal
Medpace Holdings President & CEO Sold $15.36M In Company Stock - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Connect - accessnewswire.com
Medpace Holdings (MEDP) CEO sells stock in two $620-range trades - Stock Titan
Medpace Holdings (MEDP) insider exercises 3,000 options - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation - accessnewswire.com
Medpace (MEDP) Retreats -0.57%, Breaching $586.11 Support Line 2026-09-16Bearish Sentiment - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP), Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Medpace Holdings Inc (MEDP) Stock Up 4.1% but GF Value Says Over - GuruFocus
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Medpace Holdings, Inc. (MEDP) Stock Analysis: A Resilient Growth Story With A Strong ROE - DirectorsTalk Interviews
Jefferies reiterates Medpace stock rating at Hold with $560 target - Investing.com
Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 5 Years - Benzinga
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Reach Out - ACCESS Newswire
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Medpace Holdings, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMEDP - Eastern Progress
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky - Eastern Progress
Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - easternprogress.com
Medpace Holdings, Inc. (MEDP) Stock Analysis: Evaluating the Healthcare Giant’s Growth Potential - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Medpace Holdings, Inc. of Class Action Lawsuit and Upcoming DeadlinesMEDP - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Medpace Holdings Inc. (MEDP) Key Financial Ratios – Valuation, Profitability & More - Value Research
Medpace Holdings, Inc. (MEDP), Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Medpace Holdings, Inc. (MEDP), Investigation: Bronstein, Gewirtz - The National Law Review
President & CEO Of Medpace Holdings Makes $403K Sale - benzinga.com
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term - Eastern Progress
Medpace Holdings Inc. (MEDP) Peer Comparison – Compare with Others - valueresearchonline.com
Medpace Holdings Insider Sold Shares Worth $403,176, According to a Recent SEC Filing - marketscreener.com
Medpace Holdings (MEDP) CEO sells 650 shares near $620 - Stock Titan
Medpace Holdings, Inc. (MEDP) Stock Analysis: Evaluating Its Robust Revenue Growth and Market Position - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Medpace Holdings (MEDP) director exercises options, sells 3,858 shares - Stock Titan
President & CEO At Medpace Holdings Sells $2.90M Of Stock - Benzinga
Medpace Holdings Inc Stock (MEDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):